KGK Synergize Inc.

London, Canada

KGK Synergize Inc.

London, Canada

Time filter

Source Type

Wilson D.,University of Western Ontario | Evans M.,KGK Synergize Inc. | Weaver E.,EnteraHealth Inc. | Shaw A.L.,EnteraHealth Inc. | Klein G.L.,EnteraHealth Inc.
Clinical Medicine Insights: Gastroenterology | Year: 2013

BACKGROUND: There is increased interest in combining nutritional modalities with pharmacological therapies for managing patients with diarrhea-predominant IBS (IBS-D). AIM: A randomized, double-blind, placebo-controlled study to evaluate the impact of oral serum-derived bovine immunoglobulin/protein isolate (SBI) on gastrointestinal symptom scores and quality of life (QoL) in subjects with IBS-D. METHODS: Study subjects previously diagnosed with IBS-D according to ROME II criteria were recruited from London, Ontario, Canada and assigned to receive 5 g/day SBI, 10 g/day SBI, or placebo for 6 weeks. Daily symptom frequency and severity scores and a modified IBS-36 questionnaire assessed the impact of nutritional intervention. Laboratory assessments were performed at screening and end of treatment (EOT) to evaluate safety. Within-group comparisons of changes in number of days per week with symptoms and symptom severity were conducted on the per-protocol population of subjects using a t-test. RESULTS: Subjects who received SBI at 10 g/day (N = 15) had statistically significant within-group reductions in abdominal pain (p < 0.01), loose stools (p < 0.01), bloating (p < 0.05), flatulence (p < 0.01), urgency (p < 0.05) and any symptom (p < 0.01) at EOT vs. baseline. Subjects receiving 5 g/day of SBI (N = 15) realized statistically significant within-group reductions in days with flatulence (p < 0.035), incomplete evacuation (p < 0.05), and any symptom (p < 0.01). There were no significant changes in QoL scores or in hematology or clinical chemistry among treatment groups. CONCLUSIONS: This pilot study showed that nutritional therapy with either 10 g/day or 5 g/day of SBI in 30 patients was well tolerated and resulted in statistically significant within group improvements in both symptom days and in daily symptom scores in subjects with IBS-D. Additional studies are underway with larger numbers of subjects to validate these findings. © The authors, publisher and licensee Libertas Academica Limited.


Nakao A.,University of Pittsburgh | Toyoda Y.,University of Pittsburgh | Sharma P.,KGK Synergize Inc. | Evans M.,KGK Synergize Inc. | Guthrie N.,KGK Synergize Inc.
Journal of Clinical Biochemistry and Nutrition | Year: 2010

Metabolic syndrome is characterized by cardiometabolic risk factors that include obesity, insulin resistance, hypertension and dyslipidemia. Oxidative stress is known to play a major role in the pathogenesis of metabolic syndrome. The objective of this study was to examine the effectiveness of hydrogen rich water (1.5-2 L/day) in an open label, 8-week study on 20 subjects with potential metabolic syndrome. Hydrogen rich water was produced, by placing a metallic magnesium stick into drinking water (hydrogen concentration; 0.55-0.65 mM), by the following chemical reaction; Mg + 2H2O → Mg (OH)2 + H2. The consumption of hydrogen rich water for 8 weeks resulted in a 39% increase (p<0.05) in antioxidant enzyme superoxide dismutase (SOD) and a 43% decrease (p<0.05) in thiobarbituric acid reactive substances (TBARS) in urine. Further, subjects demonstrated an 8% increase in high density lipoprotein (HDL)-cholesterol and a 13% decrease in total cholesterol/HDL- cholesterol from baseline to week 4. There was no change in fasting glucose levels during the 8 week study. In conclusion, drinking hydrogen rich water represents a potentially novel therapeutic and preventive strategy for metabolic syndrome. The portable magnesium stick was a safe, easy and effective method of delivering hydrogen rich water for daily consumption by participants in the study.


Evans M.,KGK Synergize Inc. | Elliott J.G.,DSM Nutritional Products Inc. | Sharma P.,KGK Synergize Inc. | Berman R.,DSM Nutritional Products Inc. | Guthrie N.,KGK Synergize Inc.
Maturitas | Year: 2011

Objective: To evaluate the efficacy of synthetic genistein for reducing the frequency and severity of hot flushes. Study design: A 12 week randomized double-blind, placebo-controlled study in which 84 postmenopausal women received placebo or a single 30 mg dose of synthetic genistein. Outcome measures primary: percentage change in the number of daily hot flushes from pre-treatment to week 12. Secondary: duration and severity of daily hot flushes, Greene Climacteric Scale score, serum follicle stimulating hormone (FSH), 17β-estradiol and endometrial thickness. Results: Genistein supplemented subjects completing at least 4 weeks on trial (n = 40) demonstrated a 51% reduction (9.4-4.7/day) in the number of hot flushes by week 12 compared to a 27% reduction in the placebo group (9.9-7.1/day) (p = 0.026). Subjects in the genistein group also reported significantly fewer hot flushes per day (p = 0.010) and a decrease in total duration of hot flushes per day (p = 0.009) at week 12 versus placebo. Subjects on genistein (n = 32) completing 12 weeks on trial demonstrated a 51% reduction (9.7-4.7/day) in the number of hot flushes by week 12 (p = 0.049) compared to 30% reduction in the placebo group (9.8-7.0/day) and had fewer hot flushes per day and a decrease in total duration of hot flushes per day at week 12 compared to placebo (p = 0.020 and p = 0.017, respectively). There were no differences between groups in Greene Climacteric Scale, FSH, 17β-estradiol, endometrial thickness or adverse events. Conclusions: The current study provides the first evidence that a single daily dose of 30 mg of synthetic genistein reduces hot flush frequency and duration. © 2010 Elsevier Ireland Ltd. All rights reserved.


Evans M.,KGK Synergize Inc. | Wilson D.,KGK Synergize Inc. | Guthrie N.,KGK Synergize Inc.
Journal of Functional Foods | Year: 2014

The health benefits of grapes, which contain polyphenols, are well documented. The antioxidative and cardioprotective effects of a whole grape extract (WGE) were studied in a single-centre, randomized, double-blind, placebo-controlled, 6-week pilot study conducted on 24 pre-hypertensive, overweight, and/or pre-diabetic subjects. Blood and urine biomarkers of antioxidant status were assessed at the beginning and end of the study. WGE subjects had significantly lower superoxide dismutase concentrations ( P= 0.032) and total cholesterol/HDL-C ratios ( P= 0.037), and significantly higher HDL-C levels ( P= 0.001) compared to the placebo subjects after 6. weeks. The concentration of 8-isoprostane and oxidized LDL decreased by 5% and 0.5%, respectively, for WGE subjects, but increased by 50% and 5%, respectively, for the placebo subjects. This is the first North American study to report efficacy of WGE on antioxidant status and lipid profile. © 2014 Elsevier Ltd.


Forssten S.,DuPont Company | Evans M.,KGK Synergize Inc. | Wilson D.,KGK Synergize Inc. | Ouwehand A.C.,DuPont Company
World Journal of Gastroenterology | Year: 2014

AIM: To study the effect of probiotic consumption on the faecal microbiota during and after antibiotic exposure. METHODS: A randomized, double-blind, placebo-controlled, parallel group study with a two species probiotic combination [Lactobacillus acidophilus (L. acidophilus ) ATCC 700396 and Bifidobacterium lactis (B. lactis ) ATCC SD5220] on healthy adults during and after antibiotic treatment (amoxicillin 875 and 125 mg clavulanate). The dominant faecal microbiota was studied by real time-polymerase chain reaction to determine if this probiotic preparation could facilitate restoring the microbiota to its pre-antibiotic state and influence the prevalence of beta-lactam resistance. Gastrointestinal symptoms were recorded by questionnaire and Bristol stool scale. RESULTS: Subjects on the probiotic combination had significantly higher faecal counts of L. acidophilus ATCC 700396 and B. lactis at day 8 (end of antibiotic treatment period) vs those on placebo. Furthermore, subjects on the probiotic combination had significantly higher faecal counts of L. acidophilus ATCC 700396 and B. lactis at Day 15 (end of probiotic treatment) vs those on placebo. Lactobacillus counts remained stable in the probiotic group over the course of the study, while Clostridium XIV group was higher at the end of the study and closer to baseline levels; this in contrast to the placebo group. Beta-lactam resistance in creased after antibiotic exposure and was not different between both treatment groups. Gastrointestinal symptoms were generally mild and did not differ between the treatment groups, which correlates with the generally small changes in the microbiota. CONCLUSION: Consumption of the probiotic combination mainly leads to an increase in the faecal levels of the species included in the preparation. © 2014 Baishideng Publishing Group Inc. All rights reserved.


Compositions and methods for providing anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting recommended targets for blood glucose, HbA1c, blood pressure and total cholesterol.


Patent
KGK Synergize Inc. | Date: 2015-07-29

Disclosed in certain embodiments is a canola extract comprising greater than 30% sinapic acid, pharmaceutical compositions thereof, and methods thereof.


Compositions and methods for providing anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting recommended targets for blood glucose, HbA1c, blood pressure and total cholesterol.


Trademark
KGK Synergize Inc. | Date: 2010-02-09

Dietary supplements.


Patent
KGK Synergize Inc. | Date: 2013-01-31

Compositions and methods for lightening skin are provided. A method for lightening skin may include the step of identifying skin where lightening or whitening is desired and topically applying to the skin a composition including (a) a skin lightening agent comprising a canola extract and (b) a cosmetically acceptable carrier. A method for treating hyperpigmentation may include the step of identifying skin containing areas of hyperpigmentation and topically applying to the skin a composition including (a) a canola extract and (b) a cosmetically acceptable carrier.

Loading KGK Synergize Inc. collaborators
Loading KGK Synergize Inc. collaborators